40,124 Shares in Edwards Lifesciences Corporation $EW Acquired by Wealthfront Advisers LLC

Wealthfront Advisers LLC purchased a new position in Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 40,124 shares of the medical research company’s stock, valued at approximately $3,630,000.

A number of other hedge funds also recently made changes to their positions in EW. Strategic Wealth Advisors LLC acquired a new position in shares of Edwards Lifesciences during the second quarter worth $35,000. First National Bank of Omaha purchased a new stake in Edwards Lifesciences during the 2nd quarter worth $3,720,000. Meeder Advisory Services Inc. acquired a new position in Edwards Lifesciences in the 2nd quarter worth $951,000. Harborfront Financial Group LLC purchased a new position in Edwards Lifesciences in the 2nd quarter valued at about $62,000. Finally, Tiemann Investment Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the second quarter valued at about $226,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Citigroup boosted their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Evercore restated an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Finally, Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $100.27.

Insider Activity

In other news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 25,570 shares of company stock worth $2,219,390. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $90.02 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The company’s 50-day simple moving average is $89.12 and its 200-day simple moving average is $84.63. The stock has a market capitalization of $51.83 billion, a price-to-earnings ratio of 51.74, a PEG ratio of 2.32 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period in the previous year, the company earned $0.67 earnings per share. Edwards Lifesciences’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.